伊莱利利公司主导美国减肥药市场, 而维京治疗公司则成为有前景的竞争对手. Eli Lilly dominates the U.S. weight loss drug market, while Viking Therapeutics emerges as a strong competitor with promising trial results.

伊利莉公司在美国减肥药市场占有60%的份额, 由Mounjaro和Zepbound领导, 有强的临床结果和三位数收入增长. Eli Lilly holds a 60% share of the U.S. weight loss drug market, led by Mounjaro and Zepbound, with strong clinical results and triple-digit revenue growth. 公司正在等待对其口服的提泽帕进行监管审查, 这可能会加强它的领先地位. The company awaits regulatory review for its oral tirzepatide, which could strengthen its lead. 维京治疗药物正在以其VK2735药物的关键竞争者出现,在口服和注射形式中显示出有前途的第二阶段和持续的第三阶段结果,针对类似的路径. Viking Therapeutics is emerging as a key competitor with its drug VK2735, showing promising phase 2 and ongoing phase 3 results in both oral and injectable forms, targeting similar pathways. 虽然尚未获得批准,但维京的强试验表现使其在获批后有能力参赛. Though not yet approved, Viking’s strong trial performance positions it to compete if cleared. 利来公司的股票同比下跌了8%,而维京公司则上16%. 这反映出投资者对这个不断扩大的行业的兴趣. High demand for weight loss drugs continues to drive growth, with Lilly’s stock down 8% year-to-date and Viking’s up 16%, reflecting investor interest in the expanding sector.